Comparing the cost-effectiveness of immunotherapy strategies in BRAF wild-type advanced melanoma.

Authors

Simon Zeichner

Simon B. Zeichner

Winship Cancer Institute at Emory University, Atlanta, GA

Simon B. Zeichner , Christine Kohn , Qiushi Chen , Daniel A. Goldstein , Christopher Flowers , Alberto J. Montero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research and Quality of Care

Track

Health Services Research and Quality of Care

Sub Track

Value/Cost of Care

Citation

J Clin Oncol 34, 2016 (suppl; abstr 6607)

DOI

10.1200/JCO.2016.34.15_suppl.6607

Abstract #

6607

Poster Bd #

92

Abstract Disclosures

Similar Posters

Poster

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Outcomes of immunotherapy in advanced melanoma in relation to age.

Outcomes of immunotherapy in advanced melanoma in relation to age.

First Author: Krishna Prasad Joshi

Poster

2024 ASCO Annual Meeting

Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.

Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.

First Author: Paul Lorigan

First Author: F. Stephen Hodi